TY - STD TI - National Cancer Institute: SEER Cancer Statistics Factsheets: Myeloma. Surveillance, Epidemiology, and End Results Program website. http://seer.cancer.gov/statfacts/html/mulmy.html. Accessed 6 Oct 2016. UR - http://seer.cancer.gov/statfacts/html/mulmy.html ID - ref1 ER - TY - STD TI - World Health Organization: GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. International Agency for Research on Cancer website. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed 5 Dec 2016. UR - http://globocan.iarc.fr/Pages/fact_sheets_population.aspx ID - ref2 ER - TY - JOUR AU - Durie, B. AU - Moreau, P. AU - Sonneveld, P. AU - Morgan, G. J. AU - Lahuerta, J. J. AU - Beksac, M. PY - 2012 DA - 2012// TI - Regional differences in the treatment approaches for relapsed multiple myeloma: an IMF study JO - J Clin Oncol VL - 30 ID - Durie2012 ER - TY - JOUR AU - Jordan, K. AU - Proskorovsky, I. AU - Lewis, P. AU - Ishak, J. AU - Payne, K. AU - Lordan, N. PY - 2014 DA - 2014// TI - Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study JO - Support Care Cancer VL - 22 UR - https://doi.org/10.1007/s00520-013-1991-4 DO - 10.1007/s00520-013-1991-4 ID - Jordan2014 ER - TY - JOUR AU - Kumar, S. K. AU - Therneau, T. M. AU - Gertz, M. A. AU - Lacy, M. Q. AU - Dispenzieri, A. AU - Rajkumar, S. V. PY - 2004 DA - 2004// TI - Clinical course of patients with relapsed multiple myeloma JO - Mayo Clin Proc VL - 79 UR - https://doi.org/10.4065/79.7.867 DO - 10.4065/79.7.867 ID - Kumar2004 ER - TY - JOUR AU - Mols, F. AU - Oerlemans, S. AU - Vos, A. H. AU - Koster, A. AU - Verelst, S. AU - Sonneveld, P. PY - 2012 DA - 2012// TI - Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry JO - Eur J Hematol VL - 89 UR - https://doi.org/10.1111/j.1600-0609.2012.01831.x DO - 10.1111/j.1600-0609.2012.01831.x ID - Mols2012 ER - TY - JOUR AU - Orlowski, R. Z. PY - 2013 DA - 2013// TI - Novel agents for multiple myeloma to overcome resistance in phase III clinical trials JO - Semin Oncol VL - 40 UR - https://doi.org/10.1053/j.seminoncol.2013.07.007 DO - 10.1053/j.seminoncol.2013.07.007 ID - Orlowski2013 ER - TY - JOUR AU - Armoiry, X. AU - Fagnani, F. AU - Benboubker, L. AU - Facon, T. AU - Fermand, J. P. AU - Hulin, C. PY - 2011 DA - 2011// TI - Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study JO - J Clin Pharm Ther VL - 36 UR - https://doi.org/10.1111/j.1365-2710.2009.01153.x DO - 10.1111/j.1365-2710.2009.01153.x ID - Armoiry2011 ER - TY - JOUR AU - Garrison, L. P. AU - Wang, S. T. AU - Huang, H. AU - Ba-Mancini, A. AU - Shi, H. AU - Chen, K. PY - 2013 DA - 2013// TI - The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment JO - Oncologist VL - 18 UR - https://doi.org/10.1634/theoncologist.2011-0380 DO - 10.1634/theoncologist.2011-0380 ID - Garrison2013 ER - TY - JOUR AU - Ghatnekar, O. AU - Alvegård, T. AU - Conradi, N. AU - Lenhoff, S. AU - Mellqvist, U. H. AU - Persson, U. PY - 2008 DA - 2008// TI - Direct hospital resource utilization and costs of treating patients with multiple myeloma in southwest Sweden: a 5-year retrospective analysis JO - Clin Ther VL - 30 UR - https://doi.org/10.1016/j.clinthera.2008.09.003 DO - 10.1016/j.clinthera.2008.09.003 ID - Ghatnekar2008 ER - TY - JOUR AU - Dimopoulos, M. A. AU - Goldschmidt, H. AU - Niesvizky, R. AU - Joshua, D. AU - Chng, W. -. J. AU - Oriol, A. PY - 2017 DA - 2017// TI - Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial JO - Lancet Oncol. VL - 18 UR - https://doi.org/10.1016/S1470-2045(17)30578-8 DO - 10.1016/S1470-2045(17)30578-8 ID - Dimopoulos2017 ER - TY - STD TI - National Comprehensive Cancer Network website. https://www.nccn.org/. Accessed 15 Jan 2017. UR - https://www.nccn.org/ ID - ref12 ER - TY - JOUR AU - Usmani, S. Z. AU - Rodriguez-Otero, P. AU - Bhutani, M. AU - Mateos, M. V. AU - Miguel, J. S. PY - 2015 DA - 2015// TI - Defining and treating high-risk multiple myeloma JO - Leukemia VL - 29 UR - https://doi.org/10.1038/leu.2015.209 DO - 10.1038/leu.2015.209 ID - Usmani2015 ER - TY - JOUR AU - Attal, M. AU - Lauwers-Cances, V. AU - Marit, G. AU - Caillot, D. AU - Moreau, P. AU - Facon, T. PY - 2012 DA - 2012// TI - Lenalidomide maintenance after stem-cell transplantation for multiple myeloma JO - New Engl J Med. VL - 366 UR - https://doi.org/10.1056/NEJMoa1114138 DO - 10.1056/NEJMoa1114138 ID - Attal2012 ER - TY - JOUR AU - Benboubker, L. AU - Dimopoulos, M. A. AU - Dispenzieri, A. AU - Catalano, J. AU - Belch, A. R. AU - Cavo, M. PY - 2014 DA - 2014// TI - Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma JO - New Engl J Med. VL - 371 UR - https://doi.org/10.1056/NEJMoa1402551 DO - 10.1056/NEJMoa1402551 ID - Benboubker2014 ER - TY - JOUR AU - Cerrato, C. AU - Gay, F. AU - Petrucci, M. T. AU - Pellegrino, M. AU - Gaidano, G. AU - Offidani, M. PY - 2015 DA - 2015// TI - Continuous treatment improves survival of newly diagnosed multiple myeloma patients achieving complete response: data from 5 phase III trials including young and elderly patients JO - Clin Lymphoma Myeloma Leuk VL - 15 UR - https://doi.org/10.1016/j.clml.2015.07.193 DO - 10.1016/j.clml.2015.07.193 ID - Cerrato2015 ER - TY - JOUR AU - McCarthy, P. L. AU - Owzar, K. AU - Hofmeister, C. C. AU - Hurd, D. D. AU - Hassoun, H. AU - Richardson, P. G. PY - 2012 DA - 2012// TI - Lenalidomide after stem-cell transplantation for multiple myeloma JO - New Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1114083 DO - 10.1056/NEJMoa1114083 ID - McCarthy2012 ER - TY - JOUR AU - Palumbo, A. AU - Bringhen, S. AU - Larocca, A. AU - Rossi, D. AU - Di Raimondo, F. AU - Magarotto, V. PY - 2014 DA - 2014// TI - Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.52.0023 DO - 10.1200/JCO.2013.52.0023 ID - Palumbo2014 ER - TY - JOUR AU - Palumbo, A. AU - Gay, F. AU - Cavallo, F. AU - Di Raimondo, F. AU - Larocca, A. AU - Hardan, I. PY - 2015 DA - 2015// TI - Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2014.60.2466 DO - 10.1200/JCO.2014.60.2466 ID - Palumbo2015 ER - TY - JOUR AU - Sonneveld, P. AU - Schmidt-Wolf, I. G. AU - van der Holt, B. AU - El Jarari, L. AU - Bertsch, U. AU - Salwender, H. PY - 2012 DA - 2012// TI - Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.39.6820 DO - 10.1200/JCO.2011.39.6820 ID - Sonneveld2012 ER - TY - JOUR AU - Musto, P. AU - Montefusco, V. PY - 2016 DA - 2016// TI - Are maintenance and continuous therapies indicated for every patient with multiple myeloma? JO - Expert Rev Hematol VL - 9 UR - https://doi.org/10.1080/17474086.2016.1196127 DO - 10.1080/17474086.2016.1196127 ID - Musto2016 ER - TY - JOUR AU - Dimopoulos, M. A. AU - Moreau, P. AU - Palumbo, A. AU - Joshua, D. AU - Pour, L. AU - Hájek, R. PY - 2015 DA - 2015// TI - Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomized, phase 3, open-label, multicentre study JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(15)00464-7 DO - 10.1016/S1470-2045(15)00464-7 ID - Dimopoulos2015 ER - TY - JOUR AU - Richardson, P. G. PY - 2014 DA - 2014// TI - Update on proteasome inhibitors in multiple myeloma JO - Clin Adv Hematol Oncol VL - 12 ID - Richardson2014 ER - TY - JOUR AU - Siegel, D. S. AU - Martin, T. AU - Wang, M. AU - Vij, R. AU - Jakubowiak, A. J. AU - Lonial, S. PY - 2012 DA - 2012// TI - A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma JO - Blood VL - 120 UR - https://doi.org/10.1182/blood-2012-05-425934 DO - 10.1182/blood-2012-05-425934 ID - Siegel2012 ER - TY - JOUR AU - Stewart, A. K. AU - Rajkumar, S. V. AU - Dimopoulos, M. A. AU - Masszi, T. AU - Špička, I. AU - Oriol, A. PY - 2015 DA - 2015// TI - Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma JO - New Engl J Med. VL - 372 UR - https://doi.org/10.1056/NEJMoa1411321 DO - 10.1056/NEJMoa1411321 ID - Stewart2015 ER - TY - JOUR AU - Sugumar, D. AU - Keller, J. AU - Vij, R. PY - 2015 DA - 2015// TI - Targeted treatments for multiple myeloma: specific role of carfilzomib JO - Pharmacogenomics Pers Med VL - 8 ID - Sugumar2015 ER - TY - JOUR AU - Wang, M. AU - Martin, T. AU - Bensinger, W. AU - Alsina, M. AU - Siegel, D. S. AU - Kavalerchik, E. PY - 2013 DA - 2013// TI - Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma JO - Blood VL - 122 UR - https://doi.org/10.1182/blood-2013-07-513366 DO - 10.1182/blood-2013-07-513366 ID - Wang2013 ER - TY - JOUR AU - Niesvizky, R. AU - Martin, T. G. AU - Bensinger, W. I. AU - Alsina, M. AU - Siegel, D. S. AU - Kunkel, L. A. PY - 2013 DA - 2013// TI - Phase 1b dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-12-3352 DO - 10.1158/1078-0432.CCR-12-3352 ID - Niesvizky2013 ER - TY - STD TI - Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018; https://doi.org/10.1200/JCO.2017.76.5032. ID - ref29 ER - TY - BOOK AU - Collet, D. PY - 2003 DA - 2003// TI - Modelling survival data in medical research. 2nd ed PB - Hall CY - New York ID - Collet2003 ER - TY - JOUR AU - Simon, R. AU - Makuch, R. W. PY - 1984 DA - 1984// TI - A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias JO - Stat Med VL - 3 UR - https://doi.org/10.1002/sim.4780030106 DO - 10.1002/sim.4780030106 ID - Simon1984 ER - TY - JOUR AU - Durie, B. G. AU - Harousseau, J. L. AU - Miguel, J. S. AU - Bladé, J. AU - Barlogie, B. AU - Anderson, K. PY - 2006 DA - 2006// TI - International uniform response criteria for multiple myeloma JO - Leukemia VL - 20 UR - https://doi.org/10.1038/sj.leu.2404284 DO - 10.1038/sj.leu.2404284 ID - Durie2006 ER - TY - JOUR AU - Dimopoulos, M. A. AU - Oriol, A. AU - Nahi, H. AU - San-Miguel, J. AU - Bahlis, N. J. AU - Usmani, S. Z. PY - 2016 DA - 2016// TI - Daratumumab, lenalidomide, and dexamethasone for multiple myeloma JO - New Engl J Med. VL - 375 UR - https://doi.org/10.1056/NEJMoa1607751 DO - 10.1056/NEJMoa1607751 ID - Dimopoulos2016 ER - TY - JOUR AU - Lonial, S. AU - Dimopoulos, M. AU - Palumbo, A. AU - White, D. AU - Grosicki, S. AU - Spicka, I. PY - 2015 DA - 2015// TI - Elotuzumab therapy for relapsed or refractory multiple myeloma JO - New Engl J Med. VL - 373 UR - https://doi.org/10.1056/NEJMoa1505654 DO - 10.1056/NEJMoa1505654 ID - Lonial2015 ER - TY - JOUR AU - Moreau, P. AU - Masszi, T. AU - Grzasko, N. AU - Bahlis, N. J. AU - Hansson, M. AU - Pour, L. PY - 2016 DA - 2016// TI - Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma JO - New Engl J Med. VL - 374 UR - https://doi.org/10.1056/NEJMoa1516282 DO - 10.1056/NEJMoa1516282 ID - Moreau2016 ER - TY - JOUR AU - Dimopoulos, M. A. AU - Stewart, A. K. AU - Rajkumar, V. AU - Masszi, T. AU - Oriol, A. AU - Hajek, R. PY - 2017 DA - 2017// TI - Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment JO - Blood Cancer J VL - 7 UR - https://doi.org/10.1038/bcj.2017.31 DO - 10.1038/bcj.2017.31 ID - Dimopoulos2017 ER - TY - JOUR AU - Chanan-Khan, A. AU - Giral, S. PY - 2010 DA - 2010// TI - Complete response in multiple myeloma and the impact of novel agent JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.25.4250 DO - 10.1200/JCO.2009.25.4250 ID - Chanan-Khan2010 ER - TY - JOUR AU - Van de Velde, H. AU - Liu, X. AU - Chen, G. AU - Xiangyang, L. AU - Gang, C. AU - Cakan, A. PY - 2007 DA - 2007// TI - Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma JO - Haematologica VL - 92 UR - https://doi.org/10.3324/haematol.11534 DO - 10.3324/haematol.11534 ID - Van de Velde2007 ER - TY - JOUR AU - Lonial, S. AU - Anderson, K. C. PY - 2014 DA - 2014// TI - Association of response endpoints with survival outcomes in multiple myeloma JO - Leukemia VL - 28 UR - https://doi.org/10.1038/leu.2013.220 DO - 10.1038/leu.2013.220 ID - Lonial2014 ER - TY - JOUR AU - Avet-Loiseau, H. AU - Attal, M. AU - Moreau, P. AU - Charbonnel, C. AU - Garban, F. AU - Hulin, C. PY - 2007 DA - 2007// TI - Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome JO - Blood VL - 109 UR - https://doi.org/10.1182/blood-2006-08-040410 DO - 10.1182/blood-2006-08-040410 ID - Avet-Loiseau2007 ER - TY - JOUR AU - Avet-Loiseau, H. AU - Soulier, J. AU - Fermand, J. P. AU - Yakoub-Agha, I. AU - Attal, M. AU - Hulin, C. PY - 2010 DA - 2010// TI - Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone JO - Leukemia VL - 24 UR - https://doi.org/10.1038/leu.2009.273 DO - 10.1038/leu.2009.273 ID - Avet-Loiseau2010 ER - TY - JOUR AU - Dimopoulos, M. A. AU - Weisel, K. C. AU - Song, K. W. AU - Delforge, M. AU - Karlin, L. AU - Goldschmidt, H. PY - 2015 DA - 2015// TI - Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone JO - Haematologica VL - 100 UR - https://doi.org/10.3324/haematol.2014.117077 DO - 10.3324/haematol.2014.117077 ID - Dimopoulos2015 ER - TY - JOUR AU - Kurtin, S. E. PY - 2013 DA - 2013// TI - Relapsed or relapsed/refractory multiple myeloma JO - J Adv Pract Oncol VL - 4 ID - Kurtin2013 ER - TY - JOUR AU - Jagannath, S. AU - Roy, A. AU - Kish, J. AU - Lunacsek, O. AU - Globe, D. AU - Eaddy, M. PY - 2016 DA - 2016// TI - Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices JO - Expert Rev Hematol VL - 9 UR - https://doi.org/10.1080/17474086.2016.1195254 DO - 10.1080/17474086.2016.1195254 ID - Jagannath2016 ER - TY - JOUR AU - Song, X. AU - Cong, Z. AU - Wilson, K. PY - 2016 DA - 2016// TI - Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States JO - Curr Med Res Opin VL - 32 UR - https://doi.org/10.1185/03007995.2015.1105202 DO - 10.1185/03007995.2015.1105202 ID - Song2016 ER - TY - JOUR AU - Avet-Loiseau, H. AU - Fonseca, R. AU - Siegel, D. AU - Dimopoulos, M. A. AU - Špička, I. AU - Masszi, T. PY - 2016 DA - 2016// TI - Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma JO - Blood VL - 128 UR - https://doi.org/10.1182/blood-2016-03-707596 DO - 10.1182/blood-2016-03-707596 ID - Avet-Loiseau2016 ER - TY - JOUR AU - Mateos, M. V. AU - Richardson, P. G. AU - Dimopoulos, M. A. AU - Palumbo, A. AU - Anderson, K. C. AU - Shi, H. PY - 2015 DA - 2015// TI - Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study JO - Am J Hematol VL - 90 UR - https://doi.org/10.1002/ajh.23933 DO - 10.1002/ajh.23933 ID - Mateos2015 ER - TY - JOUR AU - Jakubowiak, A. J. AU - Dytfeld, D. AU - Griffith, K. A. AU - Lebovic, D. AU - Vesole, D. H. AU - Jagannath, S. PY - 2012 DA - 2012// TI - A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a front-line treatment for multiple myeloma JO - Blood VL - 120 UR - https://doi.org/10.1182/blood-2012-04-422683 DO - 10.1182/blood-2012-04-422683 ID - Jakubowiak2012 ER - TY - JOUR AU - Jakubowiak, A. J. AU - Dytfeld, D. AU - Griffith, K. A. AU - Jasielec, J. AU - McDonnell, K. AU - Lebovic, D. PY - 2013 DA - 2013// TI - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up JO - J Clin Oncol VL - 31 ID - Jakubowiak2013 ER - TY - JOUR AU - Korde, N. AU - Zingone, A. AU - Kwok, M. L. AU - Manasanch, E. E. AU - Bhutani, M. AU - Tageja, N. PY - 2013 DA - 2013// TI - Phase II clinical and correlative study carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide extended dosing (CRD-R) induces high rates of MRD negativity in newly diagnosed multiple myeloma (MM) patients JO - Blood VL - 122 ID - Korde2013 ER - TY - STD TI - European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003790/WC500197695.pdf. Accessed 24 Feb 2017. UR - http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003790/WC500197695.pdf ID - ref51 ER -